Research programme: foetal/neonatal alloimmune thrombocytopenia therapeutic - Prophylix Pharma

Drug Profile

Research programme: foetal/neonatal alloimmune thrombocytopenia therapeutic - Prophylix Pharma

Alternative Names: anti-HPA-1a Immunoglobulin; NAITgam; Tromplate

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prophylix Pharma
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemolytic disease of newborn
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haemolytic disease of newborn

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Haemolytic-disease-of-newborn(Prevention) in Norway (IV)
  • 01 Oct 2014 Prophylix Pharma enters into a collaboration with New York Blood Center and BloodCenter of Wisconsin to develop the FNAIT propylaxis product
  • 30 Sep 2014 Prophylix Pharma and Emergent BioSolutions sign an agreement to manufacture the FNAIT prophylaxis therapeutic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top